The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis
MetadataShow full item record
Please cite this item using this persistent URLhttp://hdl.handle.net/10019.1/12443
This item appears in the following collection/s
The Positive and Negative Syndrome Scale (PANSS) is a widely used instrument for measuring severe psychopathology in adult patients with schizophrenia. Data, primarily on chronic patients, have been used to define factors for the PANSS. The present study examines the PANSS factor structure in a large sample of subjects with recent-onset schizophrenia, schizophreniform disorder and schizoaffective disorder who had been exposed to very limited antipsychotic medication. Equamax factor analysis was conducted on PANSS baseline assessments from a multicenter, 11 country drug trial that enrolled 535 patients. The forced five-factor solution essentially corresponds to the factors most frequently described previously, namely negative, positive, disorganized (or cognitive), excited and anxiety/depression. In the exploratory analysis, a seven-factor solution was obtained, with depression and anxiety symptoms separating and a motor component emerging. The results of this study partially support the use of a five-factor model for the PANSS, but suggest that scales for catatonia, depressive and anxiety syndromes should be included in future studies. © 2002 Elsevier Science B.V. All rights reserved.
Showing items related by title, author, creator and subject.
Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme Wirth M.; Tyrrell C.; Delaere K.; Sanchez-Chapado M.; Ramon J.; Wallace D.M.A.; Hetherington J.; Pina F.; Heyns C.; Borchers T.; Morris T.; Armstrong J. (2005)Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide ('Casodex'+) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150mg/day in addition to radical prostatectomy, radiotherapy or ...
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study Stryjewski M.E.; Chu V.H.; O'Riordan W.D.; Warren B.L.; Dunbar L.M.; Young D.M.; Vallee M.; Fowler Jr. V.G.; Morganroth J.; Barriere S.L.; Kitt M.M.; Corey G.R. (2006)Telavancin is a bactericidal lipoglycopeptide with a multifunctional mechanism of action. We conducted a randomized, double blind, active-control phase II trial. Patients S18 years of age with complicated skin and skin ...
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen Ruff P.; Vorobiof D.A.; Jordaan J.P.; Demetriou G.S.; Moodley S.D.; Nosworthy A.L.; Werner I.D.; Raats J.; Burgess L.J. (2009)Purpose: To determine if concomitant administration of docetaxel plus zosuquidar.3HC1 can prolong progression-free survival in patients with metastatic breast cancer. Methods: A randomized, double-blind, multicenter, ...
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J.; Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J. (2004)Objective: Platelet-activating factor (PAF) and structurally-related oxidized phospholipids are proinflammatory mediators in systemic inflammatory states such as severe sepsis. The enzyme platelet-activating factor ...
Therapeutic equivalence study of two formulations (innovator v. generic) of beclomethasone dipropionate in adult asthmatic patients Nell, H.; Louw, C. M.; Cyster, H.; Williams, Z.; Bardin,P. G.; Joubert, J. R. (2001)Objective. To study the therapeutic equivalence of two formulations (innovator v. generic) of beclomethasone dipropionate (BDP) 400 μg twice daily administered per metered dose inhaler (MDI), in adults with moderate to ...
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone Newcomer J.W.; Ratner R.E.; Eriksson J.W.; Emsley R.; Meulien D.; Miller F.; Leonova-Edlund J.; Leong R.W.; Brecher M. (2009)Objective: This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone. Method: The ...
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study Davidson M.; Emsley R.; Kramer M.; Ford L.; Pan G.; Lim P.; Eerdekens M. (2007)Background: Paliperidone extended-release tablet (paliperidone ER) is an oral psychotropic agent developed for schizophrenia treatment. Paliperidone (9-OH-risperidone, metabolite of risperidone), when used with OROS ...
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures a prospective, controlled, randomized study of four hundred and fifty patients Govender S.; Csimma C.; Genant H.K.; Valentin-Opran A.; Amit Y.; Arbel R.; Aro H.; Atar D.; Bishay M.; Borner M.G.; Chiron P.; Choong P.; Cinats J.; Courtenay B.; Feibel R.; Geulette B.; Govender S.; Gravel C.; Haas N.; Raschke M.; Hammacher E.; Van der Velde D.; Hardy P.; Holt M.; Josten C.; Ketterl R.L.; Lindeque B.; Lob G.; Mathevon H.; McCoy G.; Marsh D.; Miller R.; Munting E.; Oevre S.; Nordsletten L.; Patel A.; Pohl A.; Rennie W.; Reynders P.; Rommens P.M.; Rondia J.; Rossouw W.C.; Daneel P.J.; Ruff S.; Ruter A.; Santavirtal S.; Schidhauer T.A.; Gekle C.; Schnettler R.; Segal D.; Seiler H.; Snowdowne R.B.; Stapert J.; Taglang G.; Verdonik R.; Vogels L.; Weckbach A.; Wentzensen A.; Wisriewsk T. (2002)Background: The treatment of open fractures of the tibial shaft is often complicated by delayed union and non-union. The objective of this study was to evaluate the safety and efficacy of the use of recombinant human bone ...
Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study Schoeman J.F.; Springer P.; van Rensburg A.J.; Swanevelder S.; Hanekom W.A.; Haslett P.A.J.; Kaplan G. (2004)Childhood tuberculous meningitis is associated with serious long-term sequelae, including mental retardation, behavior disturbances, and motor handicap. Brain damage in tuberculous meningitis results from a cytokine-mediated ...
Tramadol or morphine administered during operation: A study of immediate postoperative effects after abdominal hysterectomy Coetzee J.F.; Van Loggerenberg H. (1998)Tramadol may cause awareness and EEG activation during anaesthesia. We compared tramadol with morphine, administered during wound-closure, surmising that tramadol may cause earlier awakening, more rapid recovery, less ...